Introduction
============

Cancer remains one of the major causes of deaths worldwide. In 2017, approximately 1.7 million new cases and 600 thousand deaths were estimated to occur in the USA.[@b1-ijn-13-3921] Most patients treated with conventional chemotherapy suffer from serious side effects due to non-selective action of chemotherapeutic drugs to normal cells. For a few decades, nanoparticles have been developed as a drug delivery system of various chemotherapeutic drugs to enhance drug efficacy and safety.[@b2-ijn-13-3921]--[@b4-ijn-13-3921] Nanoparticles play an important role in increasing drug concentration in cancer cells by enhancing drug accumulation by passive and active targeting mechanisms as well as by decreasing drug efflux from cancer cells. The passive targeting nanoparticle is the mechanism by which the drugs leak from blood vessels supplying cancer cells and accumulate in the cells by enhanced permeability and retention (EPR) effect.[@b5-ijn-13-3921] The active targeting nanoparticles, on the other hand, target ligands conjugated on the surface of nanoparticles, resulting in increasing cellular uptake by receptor-mediated endocytosis and therefore increased drug accumulation in cancer cells. This mechanism relies on the interaction between tumor ligands conjugated on the surface of nanoparticles and cell-surface receptors or antigens on cancer cell surfaces ([Figure 1](#f1-ijn-13-3921){ref-type="fig"}).[@b5-ijn-13-3921] Nanoparticles acting via both mechanisms have been shown to increase drug concentration in cancer cells. Active targeting nanoparticles have been shown in various studies to be more efficient in increasing drug accumulation in cancer cells and therefore play important role not only in modern cancer chemotherapy, but also in cancer therapy with traditional/herbal medicines.[@b6-ijn-13-3921]--[@b11-ijn-13-3921] A number of nanoparticle formulations derived from these active compounds have been developed for active targeting purpose to improve anticancer efficacy and to reduce side effects. The objective of this current review is to summarize the research articles relating to the application of active targeting nanoparticles delivering system for chemotherapeutic drugs derived from chemical synthesis as well as natural sources.

Materials and methods
=====================

Study selection and inclusion and exclusion criteria
----------------------------------------------------

This systematic review was conducted through the search from PubMed database up to March 2017. The following keywords were used: nanoparticle, chemotherapy, traditional medicine, herbal medicine, natural medicine, natural compound, cancer treatment, and active targeting. Inclusion criteria for selection of the searched articles were 1) articles in full text and written in English; 2) articles with in vitro or in vivo investigations of effects of nanoparticles delivering chemotherapeutic drugs or traditional/herbal medicines on efficacy and/or safety; and 3) articles with investigations of targeting and receptor/antigen. The articles with insufficient data for extraction or those with application for radiotherapy, gene therapy, photodynamic therapy, or for diagnostic purpose, or duplicate articles, or review articles were excluded from the analysis.

Data extraction and collection
------------------------------

The titles and abstracts of articles searched from PubMed database using the above mentioned keywords were initially screened to obtain relevant original research articles according to the eligibility criteria. Thereafter, the full texts of all relevant articles were carefully examined in details to confirm their compliance with the defined eligibility criteria. The studies of active targeting nanoparticles applied for both chemotherapeutic drugs and traditional/herbal medicines for cancer were classified according to the types of targeting ligands.

Results
=======

Study description
-----------------

Twenty out of 695 research articles were initially excluded from the analysis during title screening for duplicate articles. The titles together with abstracts of the remaining articles were further checked for eligibility criteria and a total of 597 articles were excluded from the analysis. Finally, 61 out of 78 articles were included in the analysis, 17 articles being excluded due to unclear/inadequate information. The flow diagram of the search process is presented in [Figure 2](#f2-ijn-13-3921){ref-type="fig"}, and the effects of active targeting nanoparticles delivering modern chemotherapeutic drugs and traditional/herbal medicines for cancer are summarized in [Tables 1](#t1-ijn-13-3921){ref-type="table"} and [2](#t2-ijn-13-3921){ref-type="table"}.

Of the 61 articles included in the analysis, 54 (88.5%) investigated nanoparticles delivering modern chemotherapeutic drugs; the majority was doxorubicin (40.7%), followed by paclitaxel (8.5%). Types of targeting ligand platforms used included proteins or small peptides (15 articles), hyaluronic acids (HAs; 10 articles), folic acids (9 articles), antibodies (5 articles), aptamers (5 articles), carbohydrates or polysaccharide (5 articles), and other molecules (5 articles). Seven articles (11.5%) investigated nanoparticles delivering traditional/herbal medicines; the majority was curcumin (42.9%). The ligand platforms used were proteins or small peptides (2 articles), HA (1 article), folic acid (1 article), antibody (1 article), aptamer (1 article), and other molecule (1 article).

Discussion
==========

Ligands for nanoparticle platform
---------------------------------

### Proteins or small peptides

Various types of proteins or small peptides were used to conjugate on the surface of nanoparticles to improve selectivity of chemotherapeutic drugs or traditional/herbal medicines to cancer cells. Transferrin, a serum glycoprotein, was one of the widely used targeting ligands. It plays a role in transferring iron from blood stream into the cells by binding to transfer-rin receptor on the cell surface. Upregulation of transferrin receptor has been reported in metastatic and drug-resistant cancer cells.[@b67-ijn-13-3921] The transferrin-conjugating nanoparticles delivering chemotherapeutic drugs have been shown to improve cellular uptake of the drugs by cancer cells and enhance in vitro and in vivo cytotoxicity. For instance, the transferrin-conjugated polyethylene glycol (PEG) nano-particle delivering hydroxycamptothecin was shown to provide longer retention time of drug in blood circulation, higher drug accumulation in cancer cells, and higher in vivo growth inhibitory activity against S180 tumor compared with non-targeted nanoparticles.[@b16-ijn-13-3921] In the study of transferrin-conjugated chitosan-PEG nanoparticles delivering paclitaxel, the targeted nanoparticles also exhibited higher cytotoxic activity to transferrin-overexpressing human non-small cell lung cancer cells (HOP-62). The respective half-maximal inhibitory concentrations (ICs~50~) were 0.3 µM and 2.0 µM.[@b17-ijn-13-3921] Apart from transferrin, arginine--glycine--aspartic acid (RGD) peptide has been used as targeting ligand to conjugate on the surface of nanoparticles to specifically target integrin α~v~β~3~ receptor. This receptor is expressed on the surface of tumor vessels and various types of cancer cells and plays important roles in tumor growth promotion, metastasis, and angiogenesis.[@b18-ijn-13-3921] A number of RGD-conjugated nanoparticles delivering chemotherapeutic drugs or traditional/herbal medicines have been developed and demonstrated to promote their delivery to the cancer cells. The cyclic arginine--glycine--aspartic acid--tyrosine--lysine c(RGDyK)-conjugated poly(trimethylene carbonate)-PEG micellar nanoparticle delivering paclitaxel was shown to enhance cytotoxic activity of the drug to integrin α~v~β~3~-overexpressing human glioblastoma cells (U87MG) compared with non-targeted nanoparticles and free drugs (mean IC~50~: 0.022 µg/mL, 0.051 µg/mL, and 0.058 µg/mL, respectively). The targeted nanoparticles also exhibited greater activity on cell apoptosis (11.23% vs 8.31% and 8.03% vs 5.38% inhibition, for early and late apoptosis, respectively). The percentages (mean values) of free drug were 6.67% and 4.32%, respectively. In addition, cellular drug uptake by U87MG cells was significantly increased.[@b18-ijn-13-3921] Superior cytotoxic potency against integrin α~v~β~3~-overexpressing human cervical carcinoma cells (HeLa) together with increased cellular uptake was also demonstrated with RGD-conjugated magnetic iron oxide nanoparticles (MIONPs)-PEG delivering doxorubicin compared with free drug and non-targeted MIONPs.[@b19-ijn-13-3921] In another study, improved cytotoxic activity by the cRGDyK-conjugated poly(2-ethyl-2-oxazoline)-poly([d]{.smallcaps},[l]{.smallcaps}-lactide) nanoparticles delivering paclitaxel over the non-targeted nanoparticles and free drug was reported (mean IC~50~: 51.16 ng/mL, 64.53 ng/mL, and 62.95 ng/mL, respectively). The enhanced activity was through direct targeting of the integrin α~v~β~3~-overexpressing prostate cancer cells (PC-3), as well as increasing of cellular uptake by PC-3 cells. Moreover, the targeted nanoparticle was also shown to enhance in vivo tumor growth inhibition rate in PC-3 tumor-bearing mice.[@b20-ijn-13-3921]

Other types of peptides that have been applied for conjugation on the surface of nanoparticles to increase selectivity of chemotherapeutic drugs to cancer cells include bombesin peptide-conjugated poly(lactic-co-glycolic acid) (PLGA) and NR7 peptide-conjugated PLGA-PEG nanoparticles. Bombesin-conjugated nanoparticles delivering docetaxel specifically bind to gastrin-releasing peptide receptor, which is overexpressed on cell surfaces of prostate, breast, ovarian, pancreatic, and colorectal cancers.[@b22-ijn-13-3921],[@b68-ijn-13-3921] This targeted nanoparticle was shown to enhance cytotoxic activity of the drug to the gastrin-releasing peptide receptor overexpressing human breast cancer cells (MDA-MB-231) compared with non-targeted nanoparticles (mean IC~50~: 35.53 ng/mL and 142.23 ng/mL, respectively).[@b22-ijn-13-3921] The NR7 peptide-conjugated PLGA-PEG nanoparticle delivering doxorubicin was used for specific drug binding to epidermal growth factor receptor (EGFR) on the cancer cell surface.[@b23-ijn-13-3921] The EGFR is a known receptor that is overexpressed on various types of cancer cell surfaces including head and neck, renal, ovarian, breast, and non-small-cell lung cancer.[@b47-ijn-13-3921],[@b69-ijn-13-3921] Activation of this receptor results in inhibition of cell apoptosis, promotion of cell proliferation, triggering of angiogenesis, and enhancement of tumor survival and metastasis. Therefore, inhibition of the function of this receptor would be expected to benefit cancer treatment. The NR7 peptide-conjugated PLGA-PEG nanoparticles exhibited higher cytotoxic activity against human ovarian carcinoma cells (SKOV3) compared with non-targeted nanoparticles (mean IC~50~: 0.05 µg/mL and 3.12 µg/mL, respectively).[@b23-ijn-13-3921] Although most studies demonstrated satisfactory outcomes of peptide- or protein-conjugated nanoparticles on targeting cancer cells, one study reported that H2009.1 peptide-conjugated liposome delivering doxorubicin to cancer cells expressing integrin α~v~β~6~ receptor could not improve the efficacy of the drug. This was due to the liposome platform preventing the targeting ligand from binding to the receptor on the cancer cell surface, and resulted in relatively low drug accumulation in cancer cells.[@b12-ijn-13-3921]

Hyaluronic acid
---------------

HA is a negatively charged linear glycosaminoglycan that consists of [d]{.smallcaps}-glucuronic acid and N-acetyl-[d]{.smallcaps}-glucosamine. It can specifically bind to CD44 receptor that is overexpressed on the cell surface of various types of cancer including lung, breast, colon, prostate, gastric, and head and neck cancers.[@b70-ijn-13-3921] HA is a widely used targeting ligand to conjugate on the surface of nanoparticles to improve selectivity of chemotherapeutic drugs to cancer cells and enhance drug efficacy and safety. In one study, HA with the two molecular weights, ie, 9.5 kDa and 35 kDa, was used to conjugate polymeric micelles delivering paclitaxel. The conjugate using 9.5 kDa HA was found to effectively increase drug cellular uptake by CD44-overexpressing human breast adenocarcinoma cells (MCF-7) compared with 35 kDa HA. In murine hepatic carcinoma (Heps), it also exhibited tumor growth inhibition at a higher rate and greater accumulation at the tumor site compared with other nanoparticle formulations.[@b27-ijn-13-3921] These results suggest that the molecular weight of HA directly influenced the efficacy of drug-loaded active targeting nanoparticles. The HA-conjugated chitosan nanoparticle delivering cisplatin was shown to increase drug cellular uptake by CD44-positive human lung cancer cells (A549) and effectively enhance cytotoxic activity of the drug, compared with non-targeted nanoparticles.[@b28-ijn-13-3921] The HA-conjugated liquid crystalline nanoparticle delivering rapamycin was reported to increase cytotoxic activity of the drug to CD44-overexpressing human breast adenocarcinoma cells (MDA-MB-231) compared with non-targeted nanoparticles (mean IC~50~: 18 µg/mL and 24.3 µg/mL, respectively). Moreover, the targeted nanoparticles also enhanced in vivo tumor growth inhibition rate in Ehrlich ascites tumor-bearing mice.[@b29-ijn-13-3921]

For traditional/herbal medicines, HA has also been used for conjugation on the surface of nanoparticles delivering 3,4-difluorobenzylidene curcumin resulting in increased cellular uptake and cytotoxic activity of the drug against human pancreatic cancer cells (MiaPaCa-2 and AsPC-1) compared with non-targeted nanoparticles (mean IC~50~: 140 nM, 160 nM, and 245 nM, respectively). Interestingly, when the CD44 receptor was blocked by free soluble HA, the cytotoxic activity to MiaPaCa-2 cells was comparable between the targeted and non-targeted nanoparticles (mean IC~50~: 234 nM and 245 nM, respectively).[@b63-ijn-13-3921] These results confirm that targeting ligand-conjugated nanoparticles enhances drug efficacy by improving cellular uptake through receptor-mediated endocytosis mechanism.

Folate
------

Folate or vitamin B9 is a stable and poorly immunogenic water-soluble vitamin. It is essential for DNA synthesis and replication, methylation, cell division and growth, and cell survival, particularly in rapidly dividing cells or cancer cells.[@b71-ijn-13-3921] Folic acid receptor is overexpressed on several cancer cell surfaces including ovarian, cervical, breast, lung, kidney, colorectal, and brain cancers.[@b71-ijn-13-3921] Using folic acid as cancer cell targeting of chemotherapeutic drug nanocarriers has been demonstrated in various studies to improve drug efficacy and safety profiles. The folic acid-conjugated PEG-PLGA nanoparticle delivering docetaxel was shown to increase drug cellular uptake by human cervical carcinoma cells (HeLa) with enhanced cytotoxic activity compared with free drug (mean IC~50~: 0.69 µg/mL and 8.29 µg/mL, respectively). It also significantly inhibited tumor growth in HeLa tumor-bearing mice.[@b36-ijn-13-3921] The folic acid-conjugated albumin nanoparticle delivering gemcitabine was shown to enhance cytotoxic activity of the drug against folic acid receptor-overexpressing human breast adenocarcinoma cells (MCF-7) compared with non-targeted nanoparticles (mean IC~50~: 0.175 µM and 0.240 µM, respectively). Similarly, in folic acid receptor-overexpressing human ovarian cancer cells (Ovcar-5), the targeted nanoparticles exhibited superior cytotoxic activity over the non-targeted nanoparticles (mean IC~50~: 0.173 µM and 0.279 µM, respectively). On the other hand, activity of the targeted nanoparticles was found similar to that of non-targeted nanoparticles against folate receptor expressing human pancreatic cancer cells (MIAPaCa-2) (mean IC~50~: 0.166 µM and 0.169 µM, respectively).[@b38-ijn-13-3921] In one study, the folic acid-conjugated PEG-PLGA nanoparticle delivering paclitaxel was shown to increase drug cellular uptake by folic acid-overexpressing human endometrial carcinoma cells (HEC-1A) with superior cytotoxic activity over the non-targeted nanoparticle (mean IC~50~: 3.43 µg/mL and 8.81 µg/mL, respectively). Moreover, it also produced significantly higher cell apoptotic activity compared with non-targeted and free drug (35.94%, 23.97% and 19%, respectively). In vivo, it produced significant tumor growth inhibition in HEC-1A tumor-bearing mice.[@b43-ijn-13-3921] For traditional/herbal medicines, folic acid-conjugated poly(epsilon-caprolactone)-PEG-poly (epsilon-caprolactone) nanoparticle delivering honokiol, a traditional Chinese medicine, was shown to increase compound cellular uptake by folic acid-overexpressing human nasopharynx carcinoma cells (HNE-1) with enhanced cytotoxic activity compared with free drug (mean IC~50~: 18.41 µg/mL and 38.59 µg/mL, respectively). Furthermore, the targeted nanoparticles also resulted in significant cell apoptotic activity compared with non-targeted nanoparticles (86.07% and 70.89%, respectively) and prolongation of median survival time compared with non-targeted nanoparticles and free drug (median survival time: 57.5 days, 42.5 days, and 34 days, respectively).[@b11-ijn-13-3921]

Antibodies or antibody fragments
--------------------------------

Antibodies or antibody fragments are one of the first targeting ligands used for conjugation on the surface of nanoparticles to target cancer cells due to their potential to specifically bind to antigens or receptors on cancer cell surfaces with high affinity. Various types of antibodies or antibody fragments have been used as targeting agents including anti-CD20 monoclonal antibody, anti-CD47 monoclonal antibody, EGFR antibody, and anti-Fas monoclonal antibody. These targeted nanoparticles have been shown to improve cellular uptake by cancer cells and enhance cytotoxic activity of the drugs to cancer cells. For instance, anti-CD20 monoclonal antibody-conjugated 1,2-distearoyl-sn-glycero-3-phosphoe-thanolamine-N-methoxypolyethylene-glycol-2000 delivers doxorubicin active carbon nanoparticles to the target CD20 receptor. It exhibited higher cytotoxic activity against CD20-positive human Burkitt's lymphoma cells (Raji) compared with non-targeted nanoparticles.[@b45-ijn-13-3921] The anti-CD47 monoclonal antibody-conjugated iron oxide magnetic nanoparticle delivering gemcitabine to the target CD47 receptor was shown to increase drug cellular uptake by human pancreatic ductal adenocarcinoma cells (Panc215 and Panc354). Their cytotoxic activity was also significantly enhanced.[@b46-ijn-13-3921] The EGFR antibody-conjugated PLGA nanoparticle delivering rapamycin was shown to exhibit higher cellular uptake by EGFR-overexpressing human breast adenocarcinoma cells (MCF-7) with enhanced cell apoptotic activity against all cell stages.[@b47-ijn-13-3921] For traditional/herbal medicines, the anti-annexin A2 antibody-conjugated PLGA nanoparticle delivering curcumin was shown to significantly increase compound cellular uptake by human breast adenocarcinoma cells (MDA-MB-231).[@b64-ijn-13-3921]

Aptamers
--------

Aptamers are short single-stranded DNA or RNA sequences that can fold to three-dimensional structure and bind to specific targets on the cancer cell surfaces that express specific targets for different aptamers. For instance, nucleolin receptor is specific for AS14111 aptamer and EpCAM protein is specific for EpCAM aptamer. The aptamer AS14111-conjugated PEG-PLGA nanoparticle delivering gemcitabine to target nucleolin receptor was shown to increase drug cellular uptake (36%) by nucleolin-overexpressing human lung cancer cells (A549) compared with non-targeted nanoparticles, with enhanced cytotoxic activity (IC~50~: 4.9 µg/mL and 28.9 µg/mL, respectively).[@b49-ijn-13-3921] The AS14111-conjugated undecylenic acid modified, thermally hydrocarbonized porous silicon (UnTH-CPSi) nanoparticle delivering methotrexate was shown to increase drug cellular uptake by nucleolin-overexpressing human breast adenocarcinoma cells (MDA-MB-231) with enhanced cytotoxic activity compared with non-targeted nanoparticles and nucleolin-negative fibroblasts cells (NIH 3T3).[@b50-ijn-13-3921] The aptamer AS14111-conjugated polymersome delivering doxorubicin was shown to increase drug cellular uptake by nucleolin-overexpressing human breast adenocarcinoma cells (MCF-7) with enhanced cytotoxic activity compared with mutated aptamer-conjugated nanoparticles (mean IC~50~: 210.9 ng/mL and 369.4 ng/mL, respectively). In addition, it also produced significant tumor growth inhibition in MCF-7 tumor-bearing mice compared with mutated aptamer-conjugated nanoparticles.[@b52-ijn-13-3921] For traditional/herbal medicines, the EpCAM aptamer-conjugated lipid-polymer-lecithin hybrid delivering curcumin was shown to increase compound cellular uptake by EpCAM-overexpressing human colon adenocarcinoma cells (HT29) compared with EpCAM-negative human embryonic kidney cells (HEK293T), (58.9%±2.6% and 72.4%±1.3%, respectively.[@b65-ijn-13-3921]

Carbohydrates or polysaccharides
--------------------------------

Galactose is one of targeting ligands in group of carbohydrates that is widely used as a targeting agent for nanoparticles. It is specifically recognized by the asialoglycoprotein receptor (ASGPR), which is overexpressed on liver cancer cell surface.[@b54-ijn-13-3921] The galactose-conjugated lithocholic acid-PEG-lactobionic acid nanoparticles delivering doxorubicin was shown to increase drug cellular uptake by human liver cancer cells (SK-HEP-1) leading to massive cell death and tumor growth inhibition compared with non-targeted nanoparticles.[@b54-ijn-13-3921] The galactose-conjugated pectin nanoparticle delivering 5-fluorouracil was shown to increase drug cellular uptake by human hepatocellular liver carcinoma cells (HepG2) with enhanced cytotoxic activity compared with free drug (mean IC~50~: 0.17×10^−4^ mol/L and 0.45×10^−4^ mol/L, respectively). Moreover, the targeted nanoparticle also improved pharmacokinetic profile of the drugs.[@b55-ijn-13-3921] On the other hand, the lactose-conjugated nanoparticle delivering doxorubicin was shown to improve drug efficacy, but not as good as galactose.[@b53-ijn-13-3921] The galactose conjugates not only specifically bind to ASGPR but also to lectin receptor, which is overexpressed on the alveolar macrophages, liver endothelial Kupffer cells, splenic macrophages, peritoneal macrophages, and macrophages of brain. The galactose-conjugated solid lipid nanoparticles delivering doxorubicin specifically targeted human lung cancer cells (A549) resulting in higher cellular uptake, enhanced cytotoxic activity, and improved pharmacokinetic profiles compared with non-targeted nanoparticles and free drug.[@b57-ijn-13-3921]

Controlled drug release of active targeting nanoparticles
---------------------------------------------------------

Controlled drug release is a property of drug delivery systems in cancer therapy. Drugs are delivered and released at specific location to avoid side effects to normal cells.[@b72-ijn-13-3921] Most studies included in this review showed biphasic characteristics of drugs released from both targeted and non-targeted nanoparticles, ie, initial burst release, followed by sustained release. For instance, about 48% and 46% of gemcitabine were released from folic acid-conjugated bovine serum albumin nanoparticles and non-targeted nanoparticles during the first 2 hours, respectively. Sustained release of up to 99% and 94% was observed at 36 hours and pH 7.4 after burst release of targeted and non-targeted nanoparticles, respectively.[@b38-ijn-13-3921] About 22% and 29% of doxorubicin were shown to release from galactose-conjugated solid lipid nanoparticles and non-targeted nanoparticles during the first 8 hours, respectively. After burst release, sustained released was observed up to 76% and 93% at 144 h and pH 7.4 for targeted and non-targeted nanoparticles, respectively.[@b57-ijn-13-3921] Moreover, in some cases, the amount of drug released from nanoparticles at endolysosomal environment (pH 5.5) or cancer cell environment (pH 6.8) was shown to be higher than that from physiological environment (pH 7.4). Up to 60% of doxorubicin was released from anti-CD20-conjugated active carbon nanoparticles and non-targeted nanoparticles at 12 hours and at pH 5.5. At pH 7.4, on the other hand, the release from nanoparticles was only 20%.[@b45-ijn-13-3921] Similarly, about 28% and 24% of gemcitabine burst were released during the first 24 hours from AS1411 aptamer-conjugated PEG-PLGA nanoparticles and non-targeted nanoparticles, respectively. After burst release, up to 44% and 41% sustained release were observed in both formulations at 120 hours and pH 5.5 for targeted and non-targeted nanoparticles, respectively. Only 30% release was observed at pH 7.4.[@b49-ijn-13-3921] In another study, doxorubicin released from chondroitin sulfate A-deoxycholic acid at day 6 was 92%, 53%, and 34% for pH 5.5, 6.8, and 7.4, respectively.[@b60-ijn-13-3921] These results suggested that conjugation of targeting ligands on the surface of nanoparticles did not affect drug release from nanoparticles. Furthermore, higher amount of drug released at acidic pH would benefit the delivery of cancer chemotherapeutic agents to cancer cells with lower side effects to normal cells.

Conclusion
==========

Active targeting nanoparticles of chemotherapeutic drugs or traditional/herbal medicines have been demonstrated in various studies both in vitro and in vivo to improve selectivity of cellular uptake of drugs to cancer cells through receptor-mediated endocytosis and/or cytotoxicity. They provide several advantages over the conventional chemotherapeutic drugs and non-targeted nanoparticle platform, particularly in regard to enhancement of drug efficacy and safety. Active targeting nanoparticles possess several advantages in cancer therapy including enhancement of selectivity of drugs to cancer cells to avoid side effects to normal cells, enhancement of drug accumulation and anticancer activity in cancer cells, and efficiency in control of drug release. Nevertheless, some disadvantages of active targeting nanoparticles include their limitation of clinical uses in only certain types of cancer that express specific receptors on the cell surfaces. Moreover, manufacturing of nanoparticle platforms is costly and requires sophisticated technology. Selection of the types of targeting nanoparticles is determined by the types of target proteins or receptors expressed on cancer cell surfaces. Clinical studies are required to confirm their application in cancer patients.
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###### 

Summary of research articles that investigated active targeting NPs delivering chemotherapeutic drugs in cancer therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ligand                                    Receptor/antigen                        Drug-NP platform                                       Types of study                                                                                                                                                                                     Outcome                                                                                                                                                                                              References                                                          
  ----------------------------------------- --------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------
  **Proteins/peptides**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  H2009.1 peptide                           Integrin α~v~β~6~                       Doxorubicin-liposome                                   In vivo: human non-small cell lung cancer cell lines (H2009) xenograft                                                                                                                             No difference in tumor targeting and tumor growth inhibition rate                                                                                                                                    No significant change in body weight                                [@b12-ijn-13-3921]

  IL-13 peptide                             IL-13Rα2 receptor                       Docetaxel-PEG-PCL                                      In vitro: human glioblastoma cell lines (U87)\                                                                                                                                                     Higher cellular uptake; 1.1-fold higher cellular apoptosis\                                                                                                                                          Not evaluated                                                       [@b13-ijn-13-3921]
                                                                                                                                           In vivo: cell lines U87 orthotopic xenograft                                                                                                                                                       Higher tumor growth inhibition rate; 1.73-fold higher tumor targeting                                                                                                                                                                                                    

  AP-1 peptide                              IL-4 receptor                           Paclitaxel-cyclodextrin                                In vivo: human breast adenocarcinoma cell lines MDA-MB-231 xenograft                                                                                                                               Specifically targeting tumor site; higher tumor growth inhibition rate                                                                                                                               Low nonspecific toxicity                                            [@b14-ijn-13-3921]

  Peptide CVKTPAQSC                         CD133+ receptor                         Docetaxel-PLA                                          In vitro: human lung cancer cell lines (A549)\                                                                                                                                                     30.5% higher cellular uptake ratio\                                                                                                                                                                  No significant change in body weight                                [@b15-ijn-13-3921]
                                                                                                                                           In vivo: cell lines A549 xenograft                                                                                                                                                                 Higher anti-metastatic efficacy                                                                                                                                                                                                                                          

  Transferrin                               Transferrin receptor                    Hydroxycamptothecin-PEG                                In vivo: murine sarcoma cell lines (S180) xenograft                                                                                                                                                9.03-Fold higher tumor accumulation; 1.85-fold higher tumor growth inhibition rate                                                                                                                   No significant change in body weight                                [@b16-ijn-13-3921]

  Transferrin                               Transferrin receptor                    Paclitaxel-PEG-chitosan                                In vitro: non-small cell lung cancer cell lines (HOP-62)                                                                                                                                           Higher cellular uptake; 6.67-fold higher cytotoxicity                                                                                                                                                Not evaluated                                                       [@b17-ijn-13-3921]

  cRGDyK                                    Integrin α~v~β~3~                       Paclitaxel-PEG-PTMC                                    In vitro: human glioblastoma -- astrocytoma, epithelial-like cell lines (U87MG)                                                                                                                    36.6% higher cellular uptake; 2.3-fold higher cytotoxicity; higher cellular apoptosis                                                                                                                Not evaluated                                                       [@b18-ijn-13-3921]

  RGDS                                      Integrin α~v~β~3~                       Doxorubicin-PEG-MIONP                                  In vitro: human cervical carcinoma cell lines (HeLa)                                                                                                                                               11-Fold higher cellular uptake; higher cytotoxicity                                                                                                                                                  Not evaluated                                                       [@b19-ijn-13-3921]

  cRGDyK                                    Integrin α~v~β~3~                       Paclitaxel-micelle                                     In vitro: human prostate cancer cell lines (PC-3)\                                                                                                                                                 1.93-Fold higher cellular uptake; 1.26-fold higher cytotoxicity\                                                                                                                                     No significant change in body weight                                [@b20-ijn-13-3921]
                                                                                                                                           In vivo: cell lines PC-3 xenograft                                                                                                                                                                 Higher tumor growth inhibition rate                                                                                                                                                                                                                                      

  RGD                                       Integrin α~v~β~3~ receptor              Doxorubicin-dendritic poly-L-lysine-gelatin            In vitro: mouse mammary breast tumor cell lines (4T1)\                                                                                                                                             Higher cytotoxicity\                                                                                                                                                                                 No significant change in body weight                                [@b21-ijn-13-3921]
                                                                                                                                           In vivo: cell lines 4T1 xenograft                                                                                                                                                                  1.18-Fold higher tumor accumulation; 10.6% higher tumor growth inhibition rate                                                                                                                                                                                           

  Bombesin peptide                          Gastrin-releasing peptide receptor      Docetaxel-PLGA                                         In vitro: human breast adenocarcinoma cell lines (MDA-MB-231)                                                                                                                                      4-Fold higher cytotoxicity                                                                                                                                                                           Not evaluated                                                       [@b22-ijn-13-3921]

  NR7 peptide                               EGFR                                    Doxorubicin-PLGA-PEG                                   In vitro: human ovarian carcinoma cell lines (SKOV3)\                                                                                                                                              3-Fold higher cellular uptake; 62.4-fold higher cytotoxicity\                                                                                                                                        Low nonspecific toxicity                                            [@b23-ijn-13-3921]
                                                                                                                                           In vivo: cell lines SKOV3 xenograft                                                                                                                                                                2.6-Fold higher tumor accumulation                                                                                                                                                                                                                                       

  LHRH peptide                              LHRHR                                   Methotrexate-HSA                                       In vitro: human breast carcinoma cell lines (T47D)                                                                                                                                                 71.5% higher cellular uptake; 8.5-fold higher cytotoxicity                                                                                                                                           Not evaluated                                                       [@b24-ijn-13-3921]

  Angiopep-2                                LRP                                     Doxorubicin-dendritic poly-L-lysine-gelatin NP         In vitro: mouse mammary breast tumor cell lines (4T1)\                                                                                                                                             Higher cellular uptake; higher cellular apoptosis\                                                                                                                                                   Low side effect to normal tissue                                    [@b25-ijn-13-3921]
                                                                                                                                           In vivo: cell lines 4T1 xenograft                                                                                                                                                                  Higher accumulation of NP in tumor; higher tumor growth inhibition rate                                                                                                                                                                                                  

  TbFGF peptide                             FGFR                                    Paclitaxel-micelle                                     In vitro: murine Lewis lung carcinoma cell lines (LL/2), human hepatocellular liver carcinoma cell lines (HepG2), human lung cancer cell lines (A549), murine colorectal cancer cell lines (C26)   18-Fold higher cytotoxicity to LL/2; higher cellular uptake by 6.6-fold for HepG2, 6.2-fold for A549, 2.9-fold for C26, and 2.7-fold for LL/2                                                        Not evaluated                                                       [@b26-ijn-13-3921]

  **Hyaluronic acid**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Hyaluronic acid                           CD44 receptor                           Topotecan hydrochloride-dendrimer                      In vitro: human colorectal cancer cell lines (HCT-116)\                                                                                                                                            Higher cellular uptake; 3-fold higher cytotoxicity compared to free drug Higher tumor growth inhibition rate; 3.6-fold and 1.7-fold higher drug accumulation in tumor compared to kidney and liver   Not evaluated                                                       [@b8-ijn-13-3921]
                                                                                                                                           In vivo: cell lines HCT-116 xenograft                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Hyaluronic acid                           CD44 receptor                           Paclitaxel-micelle                                     In vitro: human breast adenocarcinoma cell lines (MCF-7)\                                                                                                                                          4.1-Fold higher cellular uptake\                                                                                                                                                                     No significant change in body weight                                [@b27-ijn-13-3921]
                                                                                                                                           In vivo: murine hepatic carcinoma cell lines (Heps) xenograft                                                                                                                                      2.80-Fold higher tumor accumulation; 31.89% higher tumor growth inhibition rate; higher median survival time                                                                                                                                                             

  Hyaluronic acid                           CD44 receptor                           Cisplatin-chitosan                                     In vitro: human lung cancer cell lines (A549)                                                                                                                                                      Higher cellular uptake; 8-fold higher cytotoxicity                                                                                                                                                   Not evaluated                                                       [@b28-ijn-13-3921]

  Hyaluronic acid                           CD44 receptor                           Rapamycin-LbL-LCNP                                     In vitro: human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231)                                                                                                                            Higher cytotoxicity, 1.35-fold for MDA-MB-231, and 1.1-fold lower cytotoxicity to MCF-7                                                                                                              No significant change in body weight                                [@b29-ijn-13-3921]

  Hyaluronic acid                           CD44 receptor                           Doxorubicin-PBLG                                       In vivo: Ehrlich ascites tumor-bearing mice                                                                                                                                                        Higher tumor growth inhibition rate; higher survival time                                                                                                                                            Not evaluated                                                       [@b30-ijn-13-3921]

  Hyaluronic acid                           CD44 receptor                           Methotrexate-lipid-based NP                            In vivo: murine melanoma cell lines (B16F10) xenograft                                                                                                                                             Higher tumor accumulation; higher tumor growth inhibition rate                                                                                                                                       Not evaluated                                                       [@b31-ijn-13-3921]

  Hyaluronic acid                           CD44 receptor                           Doxorubicin hydroxylapatite                            In vitro: human hepatocellular carcinoma cell lines (HepG2)\                                                                                                                                       Higher cellular uptake; 46.3% higher cytotoxicity compared to free drug Higher in tumor targeting; lower tumor volume                                                                                No significant change in body weight                                [@b32-ijn-13-3921]
                                                                                                                                           In vivo: cell lines HepG2 xenograft                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Hyaluronic acid                           CD44 receptor                           Doxorubicin-HACE-PEG                                   In vitro: murine squamous cell carcinoma cell lines (SCC7) and mouse embryo fibroblast cell lines (NIH3T3)\                                                                                        Higher cellular uptake in CD44 overexpressing (SCC7) compared to CD44 negative (NIH3T3); no difference in cellular uptake compared to free drug\                                                     No significant change in body weight                                [@b33-ijn-13-3921]
                                                                                                                                           In vivo: cell lines SCC7 xenograft                                                                                                                                                                 30% higher tumor growth inhibition rate compared to free drug                                                                                                                                                                                                            

  Hyaluronic acid                           CD44 receptor                           Doxorubicin hyaluronic acid-Lys-LA10                   In vitro: doxorubicin-resistant human breast adenocarcinoma cell lines (MCF-7/ADR)\                                                                                                                Higher cellular uptake compared to free drug; no difference in cytotoxicity\                                                                                                                         No significant change in body weight and low nonspecific toxicity   [@b34-ijn-13-3921]
                                                                                                                                           In vivo: cell lines MCF-7/ADR xenograft                                                                                                                                                            Lower relative tumor volume; higher median survival time                                                                                                                                                                                                                 

  Hyaluronic acid                           CD44 receptor                           Doxorubicin-PBLG-LA                                    In vitro: human breast adenocarcinoma cell lines (MCF-7)\                                                                                                                                          10-Fold higher in cellular DOX level; higher cytotoxicity\                                                                                                                                           No significant change in body weight and low nonspecific toxicity   [@b35-ijn-13-3921]
                                                                                                                                           In vivo: cell lines MCF-7 xenograft                                                                                                                                                                No difference in tumor growth inhibition rate; higher survival time                                                                                                                                                                                                      

  **Folate**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Folic acid                                Folate receptor                         Docetaxel-PEG-PLGA                                     In vitro: human cervical carcinoma cell lines (HeLa)\                                                                                                                                              26.7-Fold higher cellular uptake; 12-fold higher cytotoxicity compared to free drug\                                                                                                                 Not evaluated                                                       [@b36-ijn-13-3921]
                                                                                                                                           In vivo: cell lines HeLa xenograft                                                                                                                                                                 Higher tumor targeting; higher tumor growth inhibition rate                                                                                                                                                                                                              

  Folic acid                                Folate receptor                         Doxorubicin-dendrimer                                  In vitro: human epidermal carcinoma cell lines (KB)                                                                                                                                                1.4-Fold higher cellular uptake; 2.2-fold higher cytotoxicity                                                                                                                                        Not evaluated                                                       [@b37-ijn-13-3921]

  Folic acid                                Folate receptor                         Gemcitabine-BSA                                        In vitro: human ovarian cancer cell lines (Ovcar-5) and human breast adenocarcinoma cell lines (MCF-7)\                                                                                            2-Fold higher cellular uptake by MCF-7; higher cytotoxicity -- 1.4-fold for MCF-7 and 1.6-fold for Ovcar-5; higher cellular apoptosis\                                                               No significant change in body weight                                [@b38-ijn-13-3921]
                                                                                                                                           In vivo: Ehrlich ascites carcinoma tumor cell-bearing mice                                                                                                                                         Higher tumor growth inhibition rate                                                                                                                                                                                                                                      

  Folic acid                                Folate receptor                         Carboplatin-PLGA-chitosan                              In vitro: human cervical carcinoma cell lines (HeLa)                                                                                                                                               Higher cellular uptake in time-dependent manner; 1.67-fold higher cytotoxicity; higher cellular apoptosis                                                                                            Not evaluated                                                       [@b39-ijn-13-3921]

  Folic acid                                Folate receptor                         Doxorubicin-polymeric NP                               In vivo: human epidermal carcinoma cell lines (KB) xenograft                                                                                                                                       1.6-Fold higher tumor growth inhibition rate                                                                                                                                                         Not evaluated                                                       [@b7-ijn-13-3921]

  Folic acid                                Folate receptor                         Doxorubicin-PEG                                        In vitro: human epidermal carcinoma cell lines (KB), human lung cancer cell lines (A549) and human hepatocellular carcinoma cell lines (HepG2)\                                                    Higher cellular uptake by KB cell; higher cytotoxicity -- 1.2-fold for A549, 3.5-fold for KB, and 2.1-fold for HepG2\                                                                                No significant change in body weight and less cardiotoxicity        [@b40-ijn-13-3921]
                                                                                                                                           In vivo: cell lines KB xenograft                                                                                                                                                                   Higher tumor targeting; higher tumor growth inhibition rate; higher survival time                                                                                                                                                                                        

  Folic acid                                Folate receptor                         Cisplatin-PEG-MSN                                      In vitro: human cervical carcinoma cell lines (HeLa)                                                                                                                                               Higher cellular uptake                                                                                                                                                                               Not evaluated                                                       [@b41-ijn-13-3921]

  Folic acid                                Folate receptor                         Doxorubicin-β-cyclodextrin                             In vitro: human placenta choriocarcinoma cell lines (JAR), human colon adenocarcinoma cell lines (HT-29), human breast adenocarcinoma cell lines (MCF-7), and mouse fibroblast cell lines (3T3)    Higher cellular uptake -- 2.09-fold by HT-29, 1.98-fold by MCF-7, and 7.31-fold by JAR; higher cytotoxicity -- 12.39-fold for JAR, 6.73-fold for HT-29, and \>1.5-fold for 3T3                       Not evaluated                                                       [@b42-ijn-13-3921]

  Folic acid                                Folate receptor                         Paclitaxel-PEG-PLGA                                    In vitro: human endometrial carcinoma cell lines (HEC-1A)\                                                                                                                                         Higher cellular uptake; 2.6-fold higher in cytotoxicity; 12% higher cellular apoptosis\                                                                                                              Not evaluated                                                       [@b43-ijn-13-3921]
                                                                                                                                           In vivo: cell lines HEC-1A xenograft                                                                                                                                                               16.48% higher tumor growth inhibition rate                                                                                                                                                                                                                               

  **Antibody**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Anti-Fas mAb                              Fas receptor                            Camptothecin-PLGA                                      In vitro: human colorectal cancer cell lines (HCT116)                                                                                                                                              Higher cellular uptake; 58.9-fold higher cytotoxicity compared to free drug                                                                                                                          Not evaluated                                                       [@b44-ijn-13-3921]

  Anti-CD20 mAb                             CD20 receptor                           Doxorubicin-DSPE-PEG2000                               In vitro: human Burkitt's lymphoma cell lines (Raji)                                                                                                                                               Selectively targeting CD-20-overexpressing cells (Raji)                                                                                                                                              Low nonspecific toxicity                                            [@b45-ijn-13-3921]

  Anti-CD47 mAb                             CD47 receptor                           Gemcitabine-MIONP                                      In vitro: human pancreatic ductal adenocarcinoma primary cells (Panc215 and Panc354)                                                                                                               Higher cellular uptake; higher cytotoxicity                                                                                                                                                          Not evaluated                                                       [@b46-ijn-13-3921]

  EGFR antibody                             EGFR                                    Rapamycin-PLGA                                         In vitro: human breast adenocarcinoma cell lines (MCF-7)                                                                                                                                           13-fold higher cellular uptake; higher cytotoxicity; 2.4-fold higher cellular apoptosis                                                                                                              Not evaluated                                                       [@b47-ijn-13-3921]

  PR81 mAb                                  MUC1 receptor                           5-fluorouracil-BSA                                     In vitro: human breast adenocarcinoma cell lines (MCF-7)                                                                                                                                           Higher cytotoxicity                                                                                                                                                                                  Not evaluated                                                       [@b48-ijn-13-3921]

  **Aptamer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Aptamer AS1411                            Nucleolin receptor                      Doxorubicin-HPAEG                                      In vitro: human breast adenocarcinoma cell lines (MCF-7)                                                                                                                                           2-fold higher cellular uptake; 1.7-fold higher cytotoxicity                                                                                                                                          Not evaluated                                                       [@b6-ijn-13-3921]

  Aptamer AS1411                            Nucleolin receptor                      Gemcitabine-PEG-PLGA                                   In vitro: human lung cancer cell lines (A549)                                                                                                                                                      36% higher cellular uptake; 5.9-fold higher cytotoxicity                                                                                                                                             Not evaluated                                                       [@b49-ijn-13-3921]

  Aptamer AS1411                            Nucleolin receptor                      Methotrexate-UnTHCPSi-PEI                              In vitro: human breast adenocarcinoma cell lines (MDA-MB-231)                                                                                                                                      1.6-fold and 4.7-fold higher cellular uptake for 3 h and 12 h, respectively; higher cytotoxicity                                                                                                     Not evaluated                                                       [@b50-ijn-13-3921]

  Aptamer AS1411                            Nucleolin receptor                      Docetaxel-mannitol-PLGA-TPGS                           In vitro: human cervical carcinoma cell lines (HeLa)\                                                                                                                                              Higher cellular uptake; 20-fold higher cytotoxicity\                                                                                                                                                 Not evaluated                                                       [@b51-ijn-13-3921]
                                                                                                                                           In vivo: cell lines HeLa xenograft                                                                                                                                                                 24.44% life time extended                                                                                                                                                                                                                                                

  Aptamer AS1411                            Nucleolin receptor                      Doxorubicin-polymersome                                In vitro: human breast adenocarcinoma cell lines (MCF-7)\                                                                                                                                          1.73-fold higher cellular uptake compared to mutated aptamer conjugates; 1.75-fold higher cytotoxicity compared to mutated aptamer conjugates\                                                       No significant change in body weight                                [@b52-ijn-13-3921]
                                                                                                                                           In vivo: cell lines MCF-7 xenograft                                                                                                                                                                1.75-fold higher tumor targeting; 21.8% higher tumor growth inhibition rate compared to mutated aptamer conjugated                                                                                                                                                       

  **Carbohydrates/polysaccharides**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Lactose                                   ASGPR                                   Doxorubicin-lactose                                    In vitro: human hepatocellular carcinoma cell lines (SMMC-7721)\                                                                                                                                   No difference in cytotoxicity and cellular apoptosis; higher cellular uptake in time-dependent manner Higher tumor targeting; no difference in tumor growth inhibition rate                          Low nonspecific toxicity                                            [@b53-ijn-13-3921]
                                                                                                                                           In vivo: cell lines SMMC-7721 xenograft                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Galactose                                 ASGPR                                   Doxorubicin-LPL                                        In vitro: human liver cancer cell lines (SK-HEP-1)\                                                                                                                                                Higher cellular uptake; higher cytotoxicity in dose-dependent manner; higher cellular apoptosis\                                                                                                     No significant change in liver enzyme                               [@b54-ijn-13-3921]
                                                                                                                                           In vivo: cell lines SK-HEP-1 orthotopic xenograft                                                                                                                                                  Higher tumor growth inhibition rate                                                                                                                                                                                                                                      

  Galactose                                 ASGPR                                   5-Fluorouracil-pectin                                  In vitro: human hepatocellular carcinoma cell lines (HepG2)                                                                                                                                        Higher cellular uptake; 2.6-fold higher cytotoxicity compared to free drug                                                                                                                           Not evaluated                                                       [@b55-ijn-13-3921]

  Galactosamine                             ASGPR                                   Paclitaxel-γ-PGA-PLA                                   In vitro: cell lines HepG2                                                                                                                                                                         Higher cytotoxicity                                                                                                                                                                                  Not evaluated                                                       [@b56-ijn-13-3921]

  Galactose                                 Lecithin receptor                       Doxorubicin solid lipid NP                             In vitro: human lung cancer cell lines (A549)                                                                                                                                                      1.5-Fold higher cellular uptake; higher cytotoxicity                                                                                                                                                 Not evaluated                                                       [@b57-ijn-13-3921]

  **Other molecules**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  EGF                                       EGFR                                    Gemcitabine-stearoyl                                   In vitro: human breast adenocarcinoma cell lines (MDA-MB-468, MDA-MB-231, and MCF-7)\                                                                                                              Higher cellular uptake in MDA-MB-468; higher cytotoxicity\                                                                                                                                           Not evaluated                                                       [@b58-ijn-13-3921]
                                                                                                                                           In vivo: cell lines MDA-MB-468 xenograft\                                                                                                                                                          Higher tumor growth inhibition rate; higher survival time\                                                                                                                                                                                                               
                                                                                                                                           Ex vivo: MDA-MB-468 tumor                                                                                                                                                                          Higher tumor accumulation                                                                                                                                                                                                                                                

  EGa1                                      EGFR                                    Doxorubicin-micelle                                    In vitro: human mouth squamous cell carcinoma cell lines UM-SCC 14C\                                                                                                                               Higher cellular uptake; higher cytotoxicity\                                                                                                                                                         Not evaluated                                                       [@b59-ijn-13-3921]
                                                                                                                                           In vivo: cell lines UM-SCC 14C xenograft                                                                                                                                                           Higher tumor targeting; higher tumor growth inhibition rate; higher median survival time                                                                                                                                                                                 

  CSA                                       CD44 receptor                           Doxorubicin chondroitin sulfate A-deoxycholic acid     In vitro: human breast adenocarcinoma cell lines (MDA-MB-231)                                                                                                                                      Higher cellular uptake compared to free drug; 1.67-fold higher cytotoxicity compared to free drug                                                                                                    Not evaluated                                                       [@b60-ijn-13-3921]

  Folic acid and bovine serum albumin       Folate receptor and SPARC               Paclitaxel-lipid                                       In vitro: human breast adenocarcinoma cell lines (MCF-7)                                                                                                                                           1.9-Fold higher cellular uptake                                                                                                                                                                      No significant change in body weight                                [@b61-ijn-13-3921]

  Hyaluronic acid and glycyrrhetinic acid   CD44 and glycyrrhetinic acid receptor   Paclitaxel glycyrrhetinic acid-graft-hyaluronic acid   In vitro: human hepatocellular carcinoma cell lines (HepG2) and murine melanoma cell lines (B16F10)                                                                                                Higher cellular uptake compared to free drug; higher cytotoxicity to HepG2                                                                                                                           Not evaluated                                                       [@b62-ijn-13-3921]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ASGPR, asialoglycoprotein receptor; BSA, bovine serum albumin; cRGDyK, cyclic arginine-glycine-aspartic acid-tyrosine-lysine; DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy polyethylene glycol-2000; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; HACE, hyaluronic acid-ceramide; HSA, human serum albumin; HPAEG, hyperbranched poly(2-((2-(acryloyloxy) ethyl)disulfanyl)ethyl 4-cyano-4-(((propylthio)-carbonothioyl)-thio)-pentanoate-co-polyethylene glycol methacrylate; IL, interleukin; LbL-LCNP, layer-by-layer-liquid crystalline nanoparticle; LHRH, luteinizing hormone-releasing hormone; LHRHR, luteinizing hormone-releasing hormone receptor; LPL, lithocholic acid-polyethylene glycol-lactobionic acid; LRP, low density lipoprotein-receptor related protein; Lys-LA10, L-lysine methyl ester-lipoic acid; mAb, monoclonal antibody; MIONP, magnetic iron oxide nanoparticle; MSN, mesoporous silica nanoparticle; NP, nanoparticle; γ-PGA-PLA, poly(gamma-glutamic acid)-poly(lactic acid); PBLG, poly(γ-benzyl L-glutamate); PBLG-LA, G-poly(c-benzyl-L-glutamate)-lipoic acid; PCL, polyethylene glycol-poly(ε-caprolactone); PEG; polyethylene glycol; PEI, polyethylenimine; PLGA, poly(lactic-co-glycolic acid); PTMC, poly(trimethylene carbonate); RGD, arginine--glycine--aspartic acid peptide; RGDS, arginine--glycine--aspartic acid--serine peptide; SPARC, secreted protein, acidic and rich in cysteine; TbFGF, truncated basic fibroblast growth factor; TPGS, tocopheryl polyethylene glycol 1000 succinate; UnTHCPSi, undecylenic acid modified, thermally hydrocarbonized porous silicon.

###### 

Summary of research articles that investigated active targeting NP delivering traditional/herbal medicines in cancer therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ligand                     Receptor/antigen                   Drug-NP platform                                       Types of study                                                                                           Outcome                                                                                                                 References                             
  -------------------------- ---------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------
  **Proteins/peptides**                                                                                                                                                                                                                                                                                                                                                                        

  cRGD                       Integrin α~v~b~3~                  Tanshinone IIA-mPEG-PLGA-PLL                           In vitro: human hepatocellular carcinoma cell lines (Hep G2)\                                            Higher cellular uptake; increase in cytotoxicity\                                                                       No significant change in body weight   [@b9-ijn-13-3921]
                                                                                                                       In vivo: cell lines Hep G2 bearing mice                                                                  Higher tumor growth inhibition rate; higher accumulation of drug in tumor; 2.5-fold higher life-extended rate                                                  

  RGD                        Integrin α~v~b~3~                  Curcumin-lipid-shell-polymer-core hybrid               In vitro: murine melanoma cell lines (B16)\                                                              No difference in cytotoxicity for B16; 19.6% higher cellular apoptosis compared to free drug\                           No significant change in body weight   [@b10-ijn-13-3921]
                                                                                                                       In vivo: cell lines B16 xenograft                                                                        Higher tumor growth inhibition rate                                                                                                                            

  **Hyaluronic acid**                                                                                                                                                                                                                                                                                                                                                                          

  Hyaluronic acid            CD44 receptor                      3,4-difluorobenzylidene curcumin-styrene maleic acid   In vitro: human pancreatic cancer cell lines (MiaPaCa-2, AsPC-1)                                         Higher cellular uptake in time-dependent manner; higher cytotoxicity -- 1.75-fold for MiaPaCa-2 and 2-fold for AsPC-1   Not evaluated                          [@b63-ijn-13-3921]

  **Folate**                                                                                                                                                                                                                                                                                                                                                                                   

  Folic acid                 Folate receptor                    Honokiol-PCEC                                          In vitro: human nasopharynx carcinoma cell lines HNE-1\                                                  Higher cellular uptake; 2.1-fold higher cytotoxicity compared with free drug; 15.2% higher percent of cell apoptosis\   Not evaluated                          [@b11-ijn-13-3921]
                                                                                                                       In vivo: cell lines HNE-1 tumor-bearing mice                                                             1.3-fold delay in tumor growth compared with free drug; 1.7-fold higher median survival time                                                                   

  **Antibody**                                                                                                                                                                                                                                                                                                                                                                                 

  Anti-annexin A2 antibody   Annexin A2 receptor                Curcumin-PLGA                                          In vitro: human breast adenocarcinoma cell lines (MDA-MB-231)                                            Higher cellular uptake                                                                                                  Not evaluated                          [@b64-ijn-13-3921]

  **Aptamer**                                                                                                                                                                                                                                                                                                                                                                                  

  EpCAM aptamer              EpCAM protein                      Curcumin-lipid-PLGA-lecithin hybrid                    In vitro: human colon adenocarcinoma cell lines (HT29) and human embryonic kidney cell lines (HEK293T)   64-fold higher cellular uptake; higher cytotoxicity compared to EpCAM-negative HEK293T                                  Not evaluated                          [@b65-ijn-13-3921]

  **Other molecules**                                                                                                                                                                                                                                                                                                                                                                          

  HACE and AMPB              CD44 receptor and salicylic acid   Manassantin B-AMPB-HACE                                In vitro: human breast adenocarcinoma cell lines (MDA-MB-231)\                                           Higher cellular uptake compared to HACE conjugates alone; higher cytotoxicity compared to HACE conjugates alone\        No significant change in body weight   [@b66-ijn-13-3921]
                                                                                                                       In vivo: cell lines MDA-MB-231 xenograft                                                                 2.4-fold higher tumor targeting compared to HACE conjugates alone; higher tumor growth inhibition rate                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AMPB, (3-aminomethylphenyl)boronic acid; cRGD, cyclic arginine--glycine--aspartic acid peptide; HACE, hyaluronic acid-ceramide; mPEG-PLGA-PLL, methoxy polyethylene glycol-poly(lactic-co-glycolic acid)-poly-L-lysine; NP, nanoparticle; PCEC, poly(ε-caprolactone)-polyethylene glycol-poly (ε-caprolactone); PLGA, poly(lactic-co-glycolic acid); RGD, arginine--glycine--aspartic acid peptide.
